Sonoma Pharmaceuticals Inc Revenue Growth Rates (SNOA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sonoma Pharmaceuticals Inc   (NASDAQ: SNOA)
 

SNOA's Revenue Growth by Quarter and Year

Sonoma Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SNOA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 6.41
FY 6.41

SNOAs Annual Revenue
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2026 $ 19.53 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 14.29 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 12.74 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 13.27 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 12.63 millions




SNOA Revenue first quarter 2026 Y/Y Growth Comment
Sonoma Pharmaceuticals Inc achieved in the first quarter 2026, above Company average Revenue rise of 59.35% year on year, to $ 6.41 millions.

Looking into first quarter 2026 results within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue growth. While Sonoma Pharmaceuticals Inc ' s Revenue jump of 59.35% ranks overall at the positon no. 509 in the first quarter 2026.


SNOA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter March - 48.27 % 9.01 % 14.29 %
3rd Quarter December - 22.19 % 13.38 % 6.8 %
2nd Quarter September - 56.42 % 31.14 % -18.02 %
1st Quarter June 59.35 % 18.58 % -1.17 % -13.82 %
FY   - 36.76 % 12.09 % -

Financial Statements
Sonoma Pharmaceuticals Inc 's first quarter 2026 Revenue $ 6.41 millions SNOA's Income Statement
Sonoma Pharmaceuticals Inc 's first quarter 2025 Revenue $ 4.02 millions Quarterly SNOA's Income Statement


SNOA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter March - 27.82 % 5.34 % 9.55 %
3rd Quarter December - -22.32 % -0.56 % 15.02 %
2nd Quarter September - 39.3 % 5.6 % -20.41 %
1st Quarter June 15.22 % 7.2 % -1.45 % 13.95 %
FY (Year on Year)   - 36.76 % 12.09 % -


Back to SNOA Growth rate Comparisons >> Back to SNOA Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #120
Overall #509

Revenue Y/Y Growth Statistics
High Average Low
136.57 % 9.8 % -56.23 %
(Jun 30 2026)   (Dec 31 2021)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #120
Overall #509
Revenue Y/Y Growth Statistics
High Average Low
136.57 % 9.8 % -56.23 %
(Jun 30 2026)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sonoma Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
148.22 % 4.93 % -56.3 %
(Jun 30 2017)  


SNOA's I. Quarter Q/Q Revenue Comment
Sonoma Pharmaceuticals Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 15.22%, to $ 6.41 millions, from $5.56 millions in the fourth quarter.

Within Medical Equipment & Supplies industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Sonoma Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 873.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #59
Healthcare Sector #200
Overall #873
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #59
Healthcare Sector #200
Overall #873
Revenue Q/Q Growth Statistics
High Average Low
148.22 % 4.93 % -56.3 %
(Jun 30 2017)  


SNOA's I. Quarter Q/Q Revenue Comment
Sonoma Pharmaceuticals Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 15.22%, to $ 6.41 millions, from $5.56 millions in the fourth quarter.

Within Medical Equipment & Supplies industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Sonoma Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 873.


Sonoma Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 21.92 $ 19.53 $ 17.72 $ 16.94 $ 14.91
Y / Y Revenue Growth (TTM) 47 % 36.68 % 26.83 % 25.02 % 17.43 %
Year on Year Revenue Growth Overall Ranking # 1078 # 117 # 414 # 1869 # 2368
Seqeuential Revenue Change (TTM) 12.24 % 10.2 % 4.63 % 13.58 % 4.37 %
Seq. Revenue Growth (TTM) Overall Ranking # 2315 # 295 # 645 # 1876 # 1739


Cumulative Revenue growth Comment
With 47% annual Revenue growth, Sonoma Pharmaceuticals Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 117 to 1078.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1078

Revenue TTM Y/Y Growth Statistics
High Average Low
47 %
 3.52 %
-40.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 350
S&P 500 # 2315
Cumulative Revenue growth Comment
With 47% annual Revenue growth, Sonoma Pharmaceuticals Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 117 to 1078.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1078

Revenue TTM Y/Y Growth Statistics
High Average Low
47 %
3.52 %
-40.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 350
S&P 500 # 2315




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SNOA's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions


About Sonoma Pharmaceuticals Inc Revenue Growth Rates (SNOA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sonoma Pharmaceuticals Inc (CIK 1367083).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001683168-26-006024
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sonoma Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.